Floatz logo

LIDOCAINE

Trigeminal Neuralgia

Beijing Tiantan HospitalSmall moleculePhase 4 / ApprovedDormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Trigeminal Neuralgia cohort.

Asset / SponsorPhaseRating
Carbamazepine
Beijing Tiantan Hospital
Phase 4BB
Galcanezumab
Duke University
Phase 4BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Vanderbilt University Medical Center
Phase 4BB
Oxcarbamezapine
Abbasi Shaheed Hospital
Phase 4BB
SUFENTANYL
Xiangya Hospital of Central South University
Phase 4BB

View all 34 →

Same molecule, other indications

LIDOCAINE is also rated in:

peripheral neuropathyDormant
BBB
Indicative ·
79 / 100
View asset →
postherpetic neuralgiaDormant
BBB
Indicative ·
78 / 100
View asset →
post-operative pain, non-human animalDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →